Viewing data from:

PAROMOMYCIN SULFATE

ANDA

PAROMOMYCIN SULFATE | A064171 | SUN PHARMACEUTICAL INDUSTRIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Paromomycin Sulfate (2023)

Total Spending

$9K

Total Claims

Beneficiaries

Avg Cost/Unit

$4.13

Spending Trend

$150K(2019)→$114K(2020)→$106K(2021)→$27K(2022)→$9K(2023)

YoY Change:+0.2%

5yr CAGR:+0.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

OLON SPAPAROMOMYCIN SULFATE

DMF 135761998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 250MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 30, 1997

No patent or exclusivity listings for this strength.